CardioMetabolic Risk Overview

CardioMetabolic Risk

To quantify cardiometabolic function is the first step in treating it. Regardless of where a patient falls in the stage of cardiometabolic decline – from perfectly healthy to advanced diabetes – it is imperative to see the big picture with Spectracell’s cardiometabolic test.

Our CardioMetabolic Panel, which combines our Pre-Diabetes and Lipoprotein Particle Profiles, precisely quantifies a person’s risk of developing diabetes or heart disease. As a clinician, you can monitor both their specific biomarkers as well as their composite risk and treat accordingly. It covers the three key facets of cardiovascular & metabolic (cardiometabolic) health: 

  • Blood sugar control
  • Lipid metabolism
  • Vascular inflammation

Lipoprotein Particle Profile (LPP®)

Cholesterol has historically been used as the standard indicator for cardiovascular disease, often being classified as “good” (HDL) or “bad” (LDL). Studies have found that it is actually the lipoprotein particles that carry the cholesterol throughout the blood, not the cholesterol within them, that are responsible for key steps in plaque formation and the development of cardiovascular disease. The small, dense, cholesterol-depleted particles impart the highest risk, as does a higher number of these lipoproteins. 

Standard cholesterol testing does not tell us enough about the particle types – or subgroups – of each of these LDL and HDL families; therefore, it misses the earliest opportunity to prevent adverse cardiovascular events, when it’s easiest to treat.



The Pre-Diabetes biomarkers identify metabolic abnormalities that may progress into diabetes.  Pre-diabetes is a condition where the body cannot efficiently metabolize foods, especially carbohydrates, resulting in impaired glycemic (blood sugar) control which may progress to diabetes when not properly treated or addressed through lifestyle changes.

SpectraCell’s Type 2 Diabetes Risk Assessment is an evaluation of specific risk factors that can indicate the presence of Pre-Diabetes and provide an assessment of a person’s risk for developing Type 2 Diabetes (Low, Moderate, or High). This test can be especially useful for identifying people within higher risk groups that are most likely to benefit from early medical and/ or lifestyle intervention. Other factors that significantly affect a pre-diabetic risk but that are not included in this report include: weight, blood pressure, smoking, inflammation, and family history.


  • “SpectraCell Micronutrient Test is a unique, scientifically-based nutrient evaluation of specific deficiencies that allows for targeted treatment. The detection of micronutrient deficiencies using this test offers a functional and biochemically unique approach to the prevention and treatment of many diseases in which the root cause originated with nutritional deficiency and subsequent downstream of cellular dysfunction and illness.”

    Mark Houston, M.D., M.S., SCH, ABAAM, FACP, FAHA Internal Medicine
  • “SpectraCell's micronutrient test allows me to diagnose specific functional deficiencies and subsequently compound supplements appropriate for the individual needs of my patients.”

    Michael O'Neal, Primary Care Team Physician Toronto Blue Jays – MLB
  • "As an interventional cardiologist and electrophysiologist dedicated to the advancement of cardiovascular health, I have come to appreciate the need for individualizing our approach to patient care. I have relied heavily upon SpectraCell's Micronutrient Test for the better part of the last decade. It gives me the ability to treat patients on a targeted and individualized level, thus eliminating the guesswork."

    Seth Baum, M.D. Cardiologist, VitalRemedy - Boca Raton, FL